The most common treatment-related AEs (incidence >30%) in patients receiving atezolizumab plus vemurafenib and cobimetinib are blood creatinine phosphokinase increased (51·3%), diarrhoea (42·2%), rash (40·9%), arthralgia (39·1%), pyrexia (38·7%), alanine aminotransferase increased (33·9%), and lipase increased (32·2%). The gene discussed is GPT; the disease is Fever.